Found an error?
Report now
Novartis CEO Vas Narasimhan is continuing his shopping spree: the Basel-based pharmaceutical company intends to acquire the US biotech company Excellergy for up to two billion US dollars. (archive picture)
Keystone
Novartis is continuing its shopping spree: the Basel-based pharmaceutical group intends to acquire the US biotech company Excellergy for up to two billion US dollars.
The transaction is expected to be completed in the second half of 2026, subject to regulatory approvals, according to a press release issued on Friday. With the planned acquisition, Novartis is strengthening its immunology strategy in the field of food allergies and other diseases associated with immediate allergic reactions.
The focus is on Excellergy's active substance Exl-111, which is currently in an early clinical test phase. It is designed to specifically block an important trigger of allergies - the so-called immunoglobulin E (IgE) - and thus alleviate symptoms faster and more effectively than previous therapies.
Allergies such as asthma, hives or food allergies could benefit from this new form of treatment. Its use in children is also being investigated.
27.03.2026, 07:27
